How Elucid Is Revolutionizing Cardiovascular CareHow Elucid Is Revolutionizing Cardiovascular Care

Elucid is on the cusp of change. Recently,  Medtech leader Scott Huennekens was named executive chairman of the board of directors for Elucid. He joins Elucid at a point of rapid growth for the company, as it moves closer towards achieving its mission of delivering unprecedented precision healthcare to reduce deaths from heart attack and stroke.

Huennekens is a proven leader in the medical device industry, with more than 25 years of experience as a successful medtech CEO, chairperson, board member, entrepreneur and investor. He has held a number of executive leadership roles within the industry, including as president and CEO at Volcano Corporation, which he guided to an IPO in 2006, prior to its sale to Philips in 2015. Huennekens has held leadership roles in more than 20 startup, growth, and public companies with market valuations that have totaled over $20 billion, including eight IPOs. More importantly, over 20 million patients have benefited from the therapies and diagnostics of these companies.

Huennekens and Elucid CEO Blake Richards join us for this episode of Let's Talk Medtech to discuss the direction of the company.